Cover Image
市場調查報告書

早產 (抑制子宮收縮) 的開發中產品分析 (2015年下半年)

Premature Labor (Tocolysis) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 245999
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
早產 (抑制子宮收縮) 的開發中產品分析 (2015年下半年) Premature Labor (Tocolysis) - Pipeline Review, H2 2016
出版日期: 2016年08月24日 內容資訊: 英文 60 Pages
簡介

早產 (早期分娩) 定義為「妊娠後不足36週便開始分娩」。主要的症狀為、骨盆、下腹部的壓迫感,及輕度的陰道痙攣、腹瀉、陰道出血、持續性沉重的腰痛等。主要的治療藥、有皮質類固醇和抑制子宮收縮劑等。

本報告提供全球各國的早期分娩 (陣痛抑制) 治療用的開發中產品的開發情形相關分析、開發中產品的最新趨勢,及臨床實驗的各階段的產品一覽、主要企業簡介、主要藥物概要 (產品概要、標的、作用機制、研究開發 (R&D) 的發展情形)、最新的產業趨勢等調查,並將其結果為您概述為以下內容。

簡介

  • 分析範圍

早產 (抑制子宮收縮) 概要

治療藥的開發

  • 早產 (抑制子宮收縮) 轉動開發中產品:概要
  • 早產 (抑制子宮收縮) 轉動開發中產品:比較分析

各企業開發中的早產(抑制子宮收縮)治療藥

大學/研究機關研究中的早產 (抑制子宮收縮) 治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

早產 (抑制子宮收縮) 治療藥:開發中產品一覽(各企業)

早產 (抑制子宮收縮) 治療藥:各研究中的產品一覽(各大學/研究機關)

早產 (抑制子宮收縮) 開發治療藥的企業

  • Actavis plc
  • GlaxoSmithKline plc
  • Kissei藥品工業
  • Lipocine Inc.
  • ObsEva SA

早產 (抑制子宮收縮):治療藥的評估

  • 單劑治療藥的情況
  • 各標靶
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • AT-814
    • 產品概要
    • 作用機制 (MoA)
    • 研究開發 (R&D) 的發展情形
  • bedoradrine sulfate
  • hydroxyprogesterone caproate
  • OBE-001
  • OBE-002
  • 第二世代孕甾酮
  • retosiban
  • 早產的孕激素受體刺激用的小分子
  • 早產的小分子

早產 (抑制子宮收縮) 治療藥:最新的藥物簡介

早產 (抑制子宮收縮) 治療藥:開發暫停的產品

早產 (抑制子宮收縮) 治療藥:開發中止的產品

早產 (抑制子宮收縮) 相關產品的開發的里程碑

  • 值得注意的最新趨勢、新聞稿 (共10件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8400IDB

Summary

Global Markets Direct's, 'Premature Labor (Tocolysis) - Pipeline Review, H2 2016', provides an overview of the Premature Labor (Tocolysis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Premature Labor (Tocolysis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Premature Labor (Tocolysis) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis)
  • The report reviews pipeline therapeutics for Premature Labor (Tocolysis) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Premature Labor (Tocolysis) therapeutics and enlists all their major and minor projects
  • The report assesses Premature Labor (Tocolysis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Premature Labor (Tocolysis)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Premature Labor (Tocolysis)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Premature Labor (Tocolysis) Overview
  • Therapeutics Development
    • Pipeline Products for Premature Labor (Tocolysis) - Overview
    • Pipeline Products for Premature Labor (Tocolysis) - Comparative Analysis
  • Premature Labor (Tocolysis) - Therapeutics under Development by Companies
  • Premature Labor (Tocolysis) - Therapeutics under Investigation by Universities/Institutes
  • Premature Labor (Tocolysis) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Premature Labor (Tocolysis) - Products under Development by Companies
  • Premature Labor (Tocolysis) - Products under Investigation by Universities/Institutes
  • Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development
    • AMAG Pharmaceuticals, Inc.
    • GlaxoSmithKline Plc
    • Juniper Pharmaceuticals, Inc.
    • Kissei Pharmaceutical Co., Ltd.
    • Lipocine Inc.
    • ObsEva SA
  • Premature Labor (Tocolysis) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • bedoradrine sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hydroxyprogesterone caproate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hydroxyprogesterone caproate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OBE-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OBE-022 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • progesterone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • retosiban - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Acute Inflammation and Premature Labor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize Progesterone Receptor for Preterm Birth - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Premature Labor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Premature Labor (Tocolysis) - Dormant Projects
  • Premature Labor (Tocolysis) - Discontinued Products
  • Premature Labor (Tocolysis) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 28, 2016: ObsEva Initiates Phase 1 Clinical Program of OBE022, a First-in-Class Orally Active Prostaglandin F2a Antagonist, for the Treatment of Preterm Labor
      • Apr 04, 2016: AMAG Pharmaceuticals Announces the U.S. Commercial Launch of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection)
      • Feb 23, 2016: AMAG Pharmaceuticals Announces FDA Approval of New Single-Dose, Preservative-Free Makena (hydroxyprogesterone caproate injection)
      • Feb 16, 2016: Lipocine Reports Positive Results of Multi-Dose Pharmacokinetic Study of LPCN 1107 for the Prevention of Preterm Birth in Pregnant Women
      • Jan 11, 2016: Juniper Pharmaceuticals provides Update on JNP-0301
      • Nov 23, 2015: AMAG Pharmaceuticals Responds to Recent Complete Response Letter From the FDA for the Single-Dose, Preservative-Free Vial of Makena
      • Nov 18, 2015: AMAG Pharmaceuticals Receives Complete Response Letter From FDA for Single-Dose, Preservative-Free Vial of Makena (hydroxyprogesterone caproate injection)
      • Nov 04, 2015: ObsEva Presents Pharmacology Data Showing that OBE002, the First Orally Active Prostaglandin F2a Antagonist, is devoid of the side effects associated with NSAID treatment of Preterm Labor
      • Sep 01, 2015: ObsEva Presents Pharmacology Data Showing that OBE001, the First Orally Active Oxytocin Antagonist, Inhibits not only Uterine Contractions but also Preterm Labor Related Inflammation Pathways
      • Jun 23, 2015: ObsEva Announces Recruitment of the First Patient in TERM Phase 2 Study - Clinical Trial to Evaluate the Safety and Efficacy of OBE001 for Delaying Spontaneous Preterm Labor in Pregnant Women
      • May 28, 2015: AMAG Pharmaceuticals Receives Complete Response Letter From FDA for the Single-Dose Vial of Makena
      • May 20, 2015: AMAG Pharmaceuticals Expands Resources Dedicated to Reducing the Risk of Preterm Birth
      • Mar 17, 2015: GSK announces start of phase III programme to evaluate retosiban for spontaneous preterm labour
      • Feb 26, 2015: ObsEva Reports Positive Phase 1 Results for the First Orally Active Oxytocin Antagonist OBE001 to Treat Preterm Labour
      • Jul 02, 2012: FDA Issues Further Guidance On K-V Pharma's Makena
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Premature Labor (Tocolysis), H2 2016
  • Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Premature Labor (Tocolysis) - Pipeline by AMAG Pharmaceuticals, Inc., H2 2016
  • Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Premature Labor (Tocolysis) - Pipeline by Juniper Pharmaceuticals, Inc., H2 2016
  • Premature Labor (Tocolysis) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
  • Premature Labor (Tocolysis) - Pipeline by Lipocine Inc., H2 2016
  • Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Premature Labor (Tocolysis) - Dormant Projects, H2 2016
  • Premature Labor (Tocolysis) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Premature Labor (Tocolysis), H2 2016
  • Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
Back to Top